| 1 | Consumer Staples | XLP | +3.8% |
| 2 | Utilities | XLU | +1.6% |
| 3 | Real Estate | XLRE | +1.0% |
| 4 | Healthcare | XLV | -1.0% |
| 5 | Financials | XLF | -2.6% |
| 6 | Consumer Disc. | XLY | -2.7% |
| 7 | Materials | XLB | -5.8% |
| 8 | Industrials | XLI | -7.1% |
| 9 | Communication | XLC | -8.2% |
| 10 | Energy | XLE | -11.2% |
| 11 | Technology | XLK | -21.0% |
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. …
| Quarter | Date | EPS est. | Actual | Surprise | YoY | Rev. est. | Actual | Surprise | YoY | Copy |
|---|---|---|---|---|---|---|---|---|---|---|
| Q3 '26 | 11/9/264:00 PM | -$0.76 | -$0.79GAAP | -3.9% | -20% | $1.0M | $0 | ⚠ Check | — | |
| Q2 '26 | 8/11/264:01 PM | -$0.71 | -$0.76GAAP | -7.0% | +1% | $1.8M | $0 | ⚠ Check | — | |
| Q1 '26 | 5/12/264:00 PM | -$0.59 | -$0.45GAAP | +23.7% | +61% | $10.1M | $20.0M | +99.0% | — | |
| Q4 '25 | 3/25/267:00 AM | -$0.71 | -$0.65GAAP | +8.5% | — | — | $0 | — | — | |
| Q3 '25 | 11/6/254:01 PM | -$0.71 | -$0.66GAAP | +7.0% | — | $2.1M | $0 | ⚠ Check | — | |
| Q2 '25 | 8/12/254:01 PM | -$1.01 | -$0.77GAAP | +23.8% | — | $6.2M | $0 | ⚠ Check | — | |
| Q1 '25 | 5/14/254:01 PM | — | -$1.15GAAP | — | -1%* | — | $0 | — | — |
⚠ Potential error in calculation, check manually. Reported revenue shows as zero, which usually means the figure is missing.
* Q1 '25: Year-ago EPS (-13.91) was before the IPO, on far fewer shares. Restated to today's share count from SEC filings: -1.135.
GAAP = diluted EPS as filed with the SEC.